Publications by authors named "Maureen Conlan"

Claim this Profile
A
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Glenn J Hanna, Myung-Ju Ahn, Jameel Muzaffar, Bhumsuk Keam, Daniel W Bowles, Maureen G Conlan

Clin Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Francois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, Guillermo Streich, Alberto J Montero, Maureen G Conlan

J Clin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer.
Patricia LoRusso, Erika Hamilton, Cynthia Ma, Neelima Vidula, Rebecca G Bagley, Maureen G Conlan

Clin Breast Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Aditya Bardia, Virginia Kaklamani, Sharon Wilks, Amy Weise, Donald Richards, Maureen G Conlan

J Clin Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women.
Maureen G Conlan, Erik F J de Vries, Awjm Glaudemans, Yamei Wang, Steven Troy

Eur J Drug Metab Pharmacokinet· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women.
Maureen G Conlan, Erik F J de Vries, Awjm Glaudemans, Yamei Wang, Steven Troy

Eur J Drug Metab Pharmacokinet· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using F-FES PET/CT imaging.
Agnes Jager, Elisabeth G E de Vries, C Willemien Menke-van der Houven van Oordt, Patrick Neven, Clasina M Venema, Maureen G Conlan

Breast Cancer Res· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.
Aditya Bardia, Philippe Aftimos, Teeru Bihani, Alfred T Anderson-Villaluz, JungAh Jung, Maureen G Conlan

Future Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Tim H Brümmendorf, Jorge E Cortes, Hanna J Khoury, Hagop M Kantarjian, Dong-Wook Kim, Maureen G Conlan

Br J Haematol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
Henry L Gomez, Manuel Philco, Patricia Pimentel, Miriam Kiyan, Maria Laura Monsalvo, Maureen G Conlan

Anticancer Drugs· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.
Abdul-Kader Souid, Ronald L Dubowy, Ashish M Ingle, Maureen G Conlan, Junfeng Sun

Pediatr Blood Cancer· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.
Paul D Mintz, Anne Neff, Malcolm MacKenzie, Lawrence T Goodnough, Christopher Hillyer, Maureen G Conlan

Transfusion· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
Sherrill J Slichter, Thomas J Raife, Kathryn Davis, Margaret Rheinschmidt, Donald H Buchholz, Maureen G Conlan

Transfusion· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial.
Alvaro Pineda, Jeffrey McCullough, Richard J Benjamin, Ritchard Cable, Ronald G Strauss, Maureen G Conlan

Transfusion· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study.
Anne C Simonsen, Pär I Johansson, Maureen G Conlan, Michele Jacquet, Jin-Sying Lin

Transfusion· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.
John D Roback, Maureen Conlan, W Lawrence Drew, Per Ljungman, W Garrett Nichols

Transfus Med Rev· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.
Scott Murphy, Edward Snyder, Ritchard Cable, Sherrill J Slichter, Ronald G Strauss, Maureen G Conlan

Transfusion· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.
Edward Snyder, Jeffrey McCullough, Sherrill J Slichter, Ronald G Strauss, Ileana Lopez-Plaza, Maureen G Conlan

Transfusion· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients.
Richard J Benjamin, Jeffrey McCullough, Paul D Mintz, Edward Snyder, William D Spotnitz, Maureen G Conlan

Transfusion· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment.
Lily Lin, Maureen G Conlan, John Tessman, George Cimino, Seth Porter

Transfusion· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
Karin Janetzko, Jean-Pierre Cazenave, Harald Klüter, Daniel Kientz, Martine Michel, Maureen G Conlan

Transfusion· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light.
Edward Snyder, Thomas Raife, Lily Lin, George Cimino, Peyton Metzel, Maureen G Conlan

Transfusion· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.
Jeffrey McCullough, David H Vesole, Richard J Benjamin, Sherrill J Slichter, Alvaro Pineda, Maureen G Conlan

Blood· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.
Dick van Rhenen, Hans Gulliksson, Jean-Pierre Cazenave, Derwood Pamphilon, Per Ljungman, Maureen Conlan

Blood· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis